The DOI matches its Crossref record; 161 of the 161 references it cites were found in a registry or an index.
CDK4 and CDK6 kinases: From basic science to cancer therapy
Open accessAbstract
Targeting cyclin-dependent kinases: Cyclin-dependent kinases (CDKs), in complex with their cyclin partners, modulate the transition through phases of the cell division cycle. Cyclin D–CDK complexes are important in cancer progression, especially for certain types of breast cancer. Fassl et al . discuss advances in understanding the biology of cyclin D–CDK complexes that have led to new concepts about how drugs that target these complexes induce cancer cell cytostasis and suggest possible combinations to widen the types of cancer that can be treated. They also discuss progress in overcoming resistance to cyclin D–CDK inhibitors and their possible application to diseases beyond cancer. —GKA
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
Palbociclib and letrozole in advanced breast cancer
Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S.-A., Gelmon, K., Harbeck, N., Lipatov, O. N., Walshe, J. M., Moulder, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607303 · Cited by 3,007
Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization
Diehl, J. A., Cheng, M., Roussel, M. F., & Sherr, C. J. (1998) · Genes & Development · doi:10.1101/gad.12.22.3499 · Cited by 2,130
Ribociclib as first-line therapy for HR-positive, advanced breast cancer
Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y.-S., Sonke, G. S., Paluch-Shimon, S., Campone, M., Blackwell, K. L., André, F., Winer, E. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609709 · Cited by 2,039
Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900
Cell cycle proteins as promising targets in cancer therapy
Otto, T., & Sicinski, P. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.138 · Cited by 1,858
Self-citationCristofanilli, M., Turner, N. C., Bondarenko, I., Ro, J., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00613-0 · Cited by 1,827
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
Goetz, M. P., Toi, M., Campone, M., Sohn, J., Paluch-Shimon, S., Huober, J., Park, I. H., Trédan, O., Chen, S.-C., Manso, L., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.6155 · Cited by 1,744
Sledge, G. W., Toi, M., Neven, P., Sohn, J., Inoue, K., Pivot, X., Burdaeva, O., Okera, M., Masuda, N., Kaufman, P. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.7585 · Cited by 1,680
Palbociclib in hormone-receptor-positive advanced breast cancer
Turner, N. C., Ro, J., André, F., Loi, S., Verma, S., Iwata, H., Harbeck, N., Loibl, S., Huang Bartlett, C., Zhang, K., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505270 · Cited by 1,590
CDK4/6 inhibition triggers anti-tumour immunity
Goel, S., DeCristo, M. J., Watt, A. C., BrinJones, H., Sceneay, J., Li, B. B., Khan, N., Ubellacker, J. M., Xie, S., Metzger-Filho, O., et al. (2017) · Nature · doi:10.1038/nature23465 · Cited by 1,513
To cycle or not to cycle: a critical decision in cancer
Malumbres, M., & Barbacid, M. (2001) · Nature Reviews Cancer · doi:10.1038/35106065 · Cited by 1,468
A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade
Jerby-Arnon, L., Shah, P., Cuoco, M. S., Rodman, C., Su, M.-J., Melms, J. C., Leeson, R., Kanodia, A., Mei, S., Lin, J.-R., et al. (2018) · Cell · doi:10.1016/j.cell.2018.09.006 · Cited by 1,429
Finn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2419 · Cited by 1,398
Gao, H., Korn, J. M., Ferretti, S., Monahan, J. E., Wang, Y., Singh, M., Zhang, C., Schnell, C., Yang, G., Zhang, Y., et al. (2015) · Nature Medicine · doi:10.1038/nm.3954 · Cited by 1,393
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
Turner, N. C., Slamon, D. J., Ro, J., Bondarenko, I., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810527 · Cited by 1,276
A novel cyclin encoded by a bcl1-linked candidate oncogene
Motokura, T., Bloom, T., Kim, H. G., Jüppner., H., Ruderman, J. V., Kronenberg, H. M., & Arnold, A. (1991) · Nature · doi:10.1038/350512a0 · Cited by 1,265
Fry, D. W., Harvey, P. J., Keller, P. R., Elliott, W. L., Meade, M., Trachet, E., Albassam, M., Zheng, X., Leopold, W. R., Pryer, N. K., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1427.3.11 · Cited by 1,236
Cyclin D1 Expression Is Regulated Positively by the p42/p44 and Negatively by the p38/HOG Pathway
Lavoie, J. N., L'Allemain, G., Brunet, A., Müller, R., & Pouysségur, J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.34.20608 · Cited by 1,211
Colony-stimulating factor 1 regulates novel cyclins during the G1 phase of the cell cycle
Matsushime, H., Roussel, M. F., Ashmun, R. A., & Sherr, C. J. (1991) · Cell · doi:10.1016/0092-8674(91)90101-4 · Cited by 1,167
Cheng, M., Olivier, P., Diehl, J. A., Fero, M., Roussel, M. F., Roberts, J. M., & Sherr, C. J. (1999) · The EMBO Journal · doi:10.1093/emboj/18.6.1571 · Cited by 1,142
Slamon, D. J., Neven, P., Chia, S., Fasching, P. A., De Laurentiis, M., Im, S.-A., Petrakova, K., Bianchi, G. V., Esteva, F. J., Martín, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.9909 · Cited by 1,121
Tripathy, D., Im, S.-A., Colleoni, M., Franke, F., Bardia, A., Harbeck, N., Hurvitz, S. A., Chow, L., Sohn, J., Lee, K. S., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30292-4 · Cited by 1,025
Johnston, S. R. D., Harbeck, N., Hegg, R., Toi, M., Martin, M., Shao, Z. M., Zhang, Q. Y., Martinez Rodriguez, J. L., Campone, M., Hamilton, E., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.02514 · Cited by 1,022
Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance
Zhang, J., Bu, X., Wang, H., Zhu, Y., Geng, Y., Nihira, N. T., Tan, Y., Ci, Y., Wu, F., Dai, X., et al. (2018) · Nature · doi:10.1038/nature25015 · Cited by 1,013
Self-citationOverall survival with ribociclib plus endocrine therapy in breast cancer
Im, S.-A., Lu, Y.-S., Bardia, A., Harbeck, N., Colleoni, M., Franke, F., Chow, L., Sohn, J., Lee, K.-S., Campos-Gomez, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903765 · Cited by 1,001
Sledge, G. W., Toi, M., Neven, P., Sohn, J., Inoue, K., Pivot, X., Burdaeva, O., Okera, M., Masuda, N., Kaufman, P. A., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2019.4782 · Cited by 991
Cellular mechanisms of tumour suppression by the retinoblastoma gene
Burkhart, D. L., & Sage, J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2399 · Cited by 974
Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice
Wang, T. C., Cardiff, R. D., Zukerberg, L., Lees, E., Arnold, A., & Schmidt, E. V. (1994) · Nature · doi:10.1038/369669a0 · Cited by 965
Specific protection against breast cancers by cyclin D1 ablation
Yu, Q., Geng, Y., & Sicinski, P. (2001) · Nature · doi:10.1038/35082500 · Cited by 934
Self-citationRetinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16
Lukas, J., Parry, D., Aagaard, L., Mann, D. J., Bartkova, J., Strauss, M., Peters, G., & Bartek, J. (1995) · Nature · doi:10.1038/375503a0 · Cited by 899
Overall survival with ribociclib plus fulvestrant in advanced breast cancer
Slamon, D. J., Neven, P., Chia, S., Fasching, P. A., De Laurentiis, M., Im, S.-A., Petrakova, K., Bianchi, G. V., Esteva, F. J., Martín, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1911149 · Cited by 865
Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6
Malumbres, M., Sotillo, R., Santamarı́a, D., Galán, J., Cerezo, A., Ortega, S., Dubus, P., & Barbacid, M. (2004) · Cell · doi:10.1016/j.cell.2004.08.002 · Cited by 793
CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation
Deng, J., Wang, E. S., Jenkins, R. W., Li, S., Dries, R., Yates, K., Chhabra, S., Huang, W., Liu, H., Aref, A. R., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0915 · Cited by 770
Herrera-Abreu, M. T., Palafox, M., Asghar, U., Rivas, M. A., Cutts, R. J., Garcia-Murillas, I., Pearson, A., Guzman, M., Rodriguez, O., Grueso, J., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-0728 · Cited by 762
Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer
(1996) · Advances in cancer research · doi:10.1016/s0065-230x(08)60352-8 · Cited by 752
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer
Johnston, S., Martin, M., Di Leo, A., Im, S.-A., Awada, A., Forrester, T., Frenzel, M., Hardebeck, M. C., Cox, J., Barriga, S., et al. (2019) · npj Breast Cancer · doi:10.1038/s41523-018-0097-z · Cited by 685
Xiong, Y., Connolly, T., Futcher, B., & Beach, D. (1991) · Cell · doi:10.1016/0092-8674(91)90100-d · Cited by 685
Dickler, M. N., Tolaney, S. M., Rugo, H. S., Cortés, J., Diéras, V., Patt, D., Wildiers, H., Hudis, C. A., O'Shaughnessy, J., Zamora, E., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0754 · Cited by 676
Cyclin D1, cancer progression, and opportunities in cancer treatment
Qie, S., & Diehl, J. A. (2016) · Journal of Molecular Medicine · doi:10.1007/s00109-016-1475-3 · Cited by 657
O'Leary, B., Cutts, R. J., Liu, Y., Hrebien, S., Huang, X., Fenwick, K., André, F., Loibl, S., Loi, S., Garcia-Murillas, I., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0264 · Cited by 650
Mouse development and cell proliferation in the absence of D-cyclins
Kozar, K., Ciemerych, M. A., Rebel, V. I., Shigematsu, H., Zagozdzon, A., Sicinska, E., Geng, Y., Yu, Q., Bhattacharya, S., Bronson, R. T., et al. (2004) · Cell · doi:10.1016/j.cell.2004.07.025 · Cited by 647
Self-citationAnders, L., Ke, N., Hydbring, P., Choi, Y. J., Widlund, H. R., Chick, J. M., Zhai, H., Vidal, M., Gygi, S. P., Braun, P., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.10.001 · Cited by 543
Alt, J. R., Cleveland, J. L., Hannink, M., & Diehl, J. A. (2000) · Genes & Development · doi:10.1101/gad.854900 · Cited by 535
Non-canonical functions of cell cycle cyclins and cyclin-dependent kinases
Hydbring, P., Malumbres, M., & Sicinski, P. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2016.27 · Cited by 528
Muise-Helmericks, R. C., Grimes, H. L., Bellacosa, A., Malstrom, S. E., Tsichlis, P. N., & Rosen, N. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.45.29864 · Cited by 511
Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway
Li, Z., Razavi, P., Li, Q., Toy, W., Liu, B., Ping, C., Hsieh, W., Sanchez-Vega, F., Brown, D. N., Da Cruz Paula, A. F., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.11.006 · Cited by 508
Cyclin-dependent kinases regulate the antiproliferative function of Smads
Matsuura, I., Denissova, N. G., Wang, G., He, D., Long, J., & Liu, F. (2004) · Nature · doi:10.1038/nature02650 · Cited by 503
Cheng, M., Sexl, V., Sherr, C. J., & Roussel, M. F. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.3.1091 · Cited by 496
Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors
Goel, S., Wang, Q., Watt, A. C., Tolaney, S. M., Dillon, D. A., Li, W., Ramm, S., Palmer, A. C., Yuzugullu, H., Varadan, V., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.02.006 · Cited by 470
Self-citationSchaer, D. A., Beckmann, R. P., Dempsey, J. A., Huber, L., Forest, A., Amaladas, N., Li, Y., Wang, Y. C., Rasmussen, E. R., Chin, D., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.02.053 · Cited by 469
Proliferation of cancer cells despite CDK2 inhibition
Tetsu, O., & McCormick, F. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00053-9 · Cited by 466
Cyclin D activates the Rb tumor suppressor by mono-phosphorylation
Narasimha, A. M., Kaulich, M., Shapiro, G. S., Choi, Y. J., Sicinski, P., & Dowdy, S. F. (2014) · eLife · doi:10.7554/elife.02872 · Cited by 461
Self-citationTurner, N. C., Liu, Y., Zhu, Z., Loi, S., Colleoni, M., Loibl, S., DeMichele, A., Harbeck, N., André, F., Bayar, M. A., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00925 · Cited by 449
CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors
Vora, S. R., Juric, D., Kim, N., Mino-Kenudson, M., Huynh, T., Costa, C., Lockerman, E. L., Pollack, S. F., Liu, M., Li, X., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.05.020 · Cited by 438
Growth suppression by p16ink4 requires functional retinoblastoma protein
Medema, R. H., Herrera, R. E., Lam, F., & Weinberg, R. A. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.14.6289 · Cited by 433
Requirement for CDK4 kinase function in breast cancer
Yu, Q., Sicinska, E., Geng, Y., Ahnström, M., Zagozdzon, A., Kong, Y., Gardner, H., Kiyokawa, H., Harris, L. N., Stål, O., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2005.12.012 · Cited by 429
Self-citationWander, S. A., Cohen, O., Gong, X., Johnson, G. N., Buendia-Buendia, J. E., Lloyd, M. R., Kim, D., Luo, F., Mao, P., Helvie, K., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1390 · Cited by 429
Puyol, M., Martín, A., Dubus, P., Mulero, F., Pizcueta, P., Khan, G., Guerra, C., Santamaría, D., & Barbacid, M. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.025 · Cited by 415
Yang, C., Li, Z., Bhatt, T., Dickler, M., Giri, D., Scaltriti, M., Baselga, J., Rosen, N., & Chandarlapaty, S. (2017) · Oncogene · doi:10.1038/onc.2016.379 · Cited by 415
Cyclin D1 in Breast Cancer Pathogenesis
Arnold, A., & Papanikolaou, A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.064 · Cited by 411
Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer
Formisano, L., Lu, Y., Servetto, A., Hanker, A. B., Jansen, V. M., Bauer, J. A., Sudhan, D. R., Guerrero-Zotano, A. L., Croessmann, S., Guo, Y., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09068-2 · Cited by 408
Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma
Rader, J., Russell, M. R., Hart, L. S., Nakazawa, M. S., Belcastro, L. T., Martinez, D., Li, Y., Carpenter, E. L., Attiyeh, E. F., Diskin, S. J., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1675 · Cited by 394
Condorelli, R., Spring, L., O’Shaughnessy, J., Lacroix, L., Bailleux, C., Scott, V., Dubois, J., Nagy, R. J., Lanman, R. B., Iafrate, A. J., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx784 · Cited by 394
Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure
Dean, J. L., Thangavel, C., McClendon, A. K., Reed, C. A., & Knudsen, E. S. (2010) · Oncogene · doi:10.1038/onc.2010.154 · Cited by 393
Mechanisms of Sensitivity and Resistance to CDK4/6 Inhibition
Álvarez-Fernández, M., & Malumbres, M. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.010 · Cited by 390
Lukas, J., Bartkova, J., Rohde, M., Strauss, M., & Bartek, J. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.5.2600 · Cited by 366
The metabolic function of cyclin D3-CDK6 kinase in cancer cell survival
Wang, H., Nicolay, B. N., Chick, J. M., Gao, X., Geng, Y., Ren, H., Gao, H., Yang, G., Williams, J. A., Suski, J. M., et al. (2017) · Nature · doi:10.1038/nature22797 · Cited by 347
Self-citationThe Requirement for Cyclin D Function in Tumor Maintenance
Choi, Y. J., Li, X., Hydbring, P., Sanda, T., Stefano, J., Christie, A. L., Signoretti, S., Look, A. T., Kung, A. L., von Boehmer, H., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.09.015 · Cited by 342
Transcriptional regulation of the cyclin D1 gene at a glance
Klein, E. A., & Assoian, R. K. (2008) · Journal of Cell Science · doi:10.1242/jcs.039131 · Cited by 341
Characterization of a candidate bcl-1 gene.
Withers, D. A., Harvey, R. C., Faust, J. B., Melnyk, O., Carey, K., & Meeker, T. C. (1991) · Molecular and Cellular Biology · doi:10.1128/mcb.11.10.4846 · Cited by 340
Rescue of Cyclin D1 Deficiency by Knockin Cyclin E
Geng, Y., Whoriskey, W., Park, M. Y., Bronson, R. T., Medema, R. H., Li, T., Weinberg, R. A., & Sicinski, P. (1999) · Cell · doi:10.1016/s0092-8674(00)80788-6 · Cited by 336
Self-citationCyclin D1-dependent kinase activity in murine development and mammary tumorigenesis
Landis, M. W., Pawlyk, B. S., Li, T., Sicinski, P., & Hinds, P. W. (2006) · Cancer Cell · doi:10.1016/j.ccr.2005.12.019 · Cited by 329
Lukas, J., Bartkova, J., & Bartek, J. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.12.6917 · Cited by 327
Michaud, K., Solomon, D. A., Oermann, E., Kim, J.-S., Zhong, W.-Z., Prados, M. D., Ozawa, T., James, C. D., & Waldman, T. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4559 · Cited by 319
CDK4/6 inhibition in breast cancer: current practice and future directions
Pernas, S., Tolaney, S. M., Winer, E. P., & Goel, S. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918786451 · Cited by 316
Cyclin D-Cdk4,6 Drives Cell-Cycle Progression via the Retinoblastoma Protein’s C-Terminal Helix
Topacio, B. R., Zatulovskiy, E., Cristea, S., Xie, S., Tambo, C. S., Rubin, S. M., Sage, J., Kõivomägi, M., & Skotheim, J. M. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.03.020 · Cited by 305
Vijayaraghavan, S., Karakas, C., Doostan, I., Chen, X., Bui, T., Yi, M., Raghavendra, A. S., Zhao, Y., Bashour, S. I., Ibrahim, N. K., et al. (2017) · Nature Communications · doi:10.1038/ncomms15916 · Cited by 292
Raub, T. J., Wishart, G. N., Kulanthaivel, P., Staton, B. A., Ajamie, R. T., Sawada, G. A., Gelbert, L. M., Shannon, H. E., Sanchez-Martinez, C., & De Dios, A. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.062745 · Cited by 284
PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3Kα Inhibitors in Breast Cancer
Costa, C., Wang, Y., Ly, A., Hosono, Y., Murchie, E., Walmsley, C. S., Huynh, T., Healy, C., Peterson, R., Yanase, S., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0830 · Cited by 270
Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF-κB Activation and PD-L1 Expression
Jin, X., Ding, D., Yan, Y., Li, H., Wang, B., Ma, L., Ye, Z., Ma, T., Wu, Q., Rodrigues, D. N., et al. (2019) · Molecular Cell · doi:10.1016/j.molcel.2018.10.034 · Cited by 257
Jansen, V. M., Bhola, N. E., Bauer, J. A., Formisano, L., Lee, K.-M., Hutchinson, K. E., Witkiewicz, A. K., Moore, P. D., Estrada, M. V., Sánchez, V., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2653 · Cited by 244
Aggarwal, P., Vaites, L. P., Kim, J. K., Mellert, H., Gurung, B., Nakagawa, H., Herlyn, M., Hua, X., Rustgi, A. K., McMahon, S. B., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.08.012 · Cited by 242
Gong, X., Litchfield, L. M., Webster, Y., Chio, L.-C., Wong, S. S., Stewart, T. R., Dowless, M., Dempsey, J., Zeng, Y., Torres, R., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.11.006 · Cited by 236
p27 allosterically activates cyclin-dependent kinase 4 and antagonizes palbociclib inhibition
Guiley, K. Z., Stevenson, J. W., Lou, K., Barkovich, K. J., Kumarasamy, V., Wijeratne, T. U., Bunch, K. L., Tripathi, S., Knudsen, E. S., Witkiewicz, A. K., et al. (2019) · Science · doi:10.1126/science.aaw2106 · Cited by 229
Dean, J. L., McClendon, A. K., Hickey, T. E., Butler, L. M., Tilley, W. D., Witkiewicz, A. K., & Knudsen, E. S. (2012) · Cell Cycle · doi:10.4161/cc.21195 · Cited by 226
Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM
Wiedemeyer, W. R., Dunn, I. F., Quayle, S. N., Zhang, J., Chheda, M. G., Dunn, G. P., Zhuang, L., Rosenbluh, J., Chen, S., Xiao, Y., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1001613107 · Cited by 223
Finn, R. S., Liu, Y., Zhu, Z., Martin, M., Rugo, H. S., Diéras, V., Im, S.-A., Gelmon, K. A., Harbeck, N., Lu, D. R., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0751 · Cited by 201
Franco, J., Balaji, U., Freinkman, E., Witkiewicz, A. K., & Knudsen, E. S. (2016) · Cell Reports · doi:10.1016/j.celrep.2015.12.094 · Cited by 199
Combined CDK4/6 and PI3Kα Inhibition Is Synergistic and Immunogenic in Triple-Negative Breast Cancer
Teo, Z. L., Versaci, S., Dushyanthen, S., Caramia, F., Savas, P., Mintoff, C. P., Zethoven, M., Virassamy, B., Luen, S. J., McArthur, G. A., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-2210 · Cited by 196
Preclinical characterization of abemaciclib in hormone receptor positive breast cancer
Torres-Guzmán, R., Calsina, B., Hermoso, A., Baquero, C., Alvarez, B., Amat, J., McNulty, A. M., Gong, X., Boehnke, K., Du, J., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17778 · Cited by 196
Cen, L., Carlson, B. L., Schroeder, M. A., Ostrem, J. L., Kitange, G. J., Mladek, A. C., Fink, S. R., Decker, P. A., Wu, W., Kim, J.-S., et al. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos114 · Cited by 189
Expanding control of the tumor cell cycle with a CDK2/4/6 inhibitor
Freeman-Cook, K., Hoffman, R. L., Miller, N., Almaden, J., Chionis, J., Zhang, Q., Eisele, K., Liu, C., Zhang, C., Huser, N., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.08.009 · Cited by 189
CDK4/6 Inhibitors Impair Recovery from Cytotoxic Chemotherapy in Pancreatic Adenocarcinoma
Salvador-Barbero, B., Álvarez-Fernández, M., Zapatero-Solana, E., El Bakkali, A., Menéndez, M. D. C., López-Casas, P. P., Di Domenico, T., Xie, T., VanArsdale, T., Shields, D. J., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.01.007 · Cited by 176
CRL4AMBRA1 is a master regulator of D-type cyclins
Simoneschi, D., Rona, G., Zhou, N., Jeong, Y.-T., Jiang, S., Milletti, G., Arbini, A. A., O’Sullivan, A., Wang, A. A., Nithikasem, S., et al. (2021) · Nature · doi:10.1038/s41586-021-03445-y · Cited by 172
Johnson, S. M., Torrice, C. D., Bell, J. F., Monahan, K. B., Jiang, Q., Wang, Y., Ramsey, M. R., Jin, J., Wong, K.-K., Su, L., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41402 · Cited by 168
Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion
He, S., Roberts, P. J., Sorrentino, J. A., Bisi, J., White, H. S., Tiessen, R. G., Makhuli, K. M., Wargin, W. A., Tadema, H., van Hoogdalem, E., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal3986 · Cited by 167
The AMBRA1 E3 ligase adaptor regulates the stability of cyclin D
Chaikovsky, A. C., Li, C., Jeng, E. E., Loebell, S., Lee, M. C., Murray, C. W., Cheng, R., Demeter, J., Swaney, D. L., Chen, S.-H., et al. (2021) · Nature · doi:10.1038/s41586-021-03474-7 · Cited by 167
Weiss, J. M., Csoszi, T., Maglakelidze, M., Hoyer, R. J., Beck, J. T., Domine Gomez, M., Lowczak, A., Aljumaily, R., Rocha Lima, C. M., Boccia, R. V., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz278 · Cited by 165
Modification of the DNA Damage Response by Therapeutic CDK4/6 Inhibition
Dean, J. L., McClendon, A. K., & Knudsen, E. S. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.365494 · Cited by 160
AMBRA1 regulates cyclin D to guard S-phase entry and genomic integrity
Maiani, E., Milletti, G., Nazio, F., Holdgaard, S. G., Bartkova, J., Rizza, S., Cianfanelli, V., Lorente, M., Simoneschi, D., Di Marco, M., et al. (2021) · Nature · doi:10.1038/s41586-021-03422-5 · Cited by 160
Switching cyclin D-Cdk4 kinase activity on and off
Blain, S. W. (2008) · Cell Cycle · doi:10.4161/cc.7.7.5637 · Cited by 155
Yoshida, A., Lee, E. K., & Diehl, J. A. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2931 · Cited by 153
ATP-competitive inhibitors block protein kinase recruitment to the Hsp90-Cdc37 system
Polier, S., Samant, R. S., Clarke, P. A., Workman, P., Prodromou, C., & Pearl, L. H. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1212 · Cited by 145
Uras, I. Z., Walter, G. J., Scheicher, R., Bellutti, F., Prchal‐Murphy, M., Tigan, A.-S., Valent, P., Heidel, F. H., Kubicek, S., Scholl, C., et al. (2016) · Blood · doi:10.1182/blood-2015-11-683581 · Cited by 145
PRMT5 is required for lymphomagenesis triggered by multiple oncogenic drivers
Li, Y., Chitnis, N., Nakagawa, H., Kita, Y., Natsugoe, S., Yang, Y., Li, Z., Wasik, M., Klein-Szanto, A. J. P., Rustgi, A. K., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0625 · Cited by 143
Kovatcheva, M., Liu, D. D., Dickson, M. A., Klein, M. E., O’Connor, R., Wilder, F. O., Socci, N. D., Tap, W. D., Schwartz, G. K., Singer, S., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3364 · Cited by 142
Cornell, L., Wander, S. A., Visal, T. H., Wagle, N., & Shapiro, G. I. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.02.023 · Cited by 142
Cdk4 and Cdk6 Couple the Cell-Cycle Machinery to Cell Growth via mTORC1
Romero‐Pozuelo, J., Figlia, G., Kaya, O., Martín-Villalba, A., & Teleman, A. A. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.03.068 · Cited by 139
Regulation of PRMT5–MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma
AbuHammad, S., Cullinane, C. M., Martin, C., Bacolas, Z., Ward, T. A., Chen, H., Slater, A. A., Ardley, K., Kirby, L., Chan, K. T., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1901323116 · Cited by 136
Wang, L., Wang, J., Blaser, B. W., Duchemin, A.-M., Kusewitt, D. F., Liu, T., Caligiuri, M. A., & Briesewitz, R. (2007) · Blood · doi:10.1182/blood-2007-02-071266 · Cited by 134
Differential Modification of p27 Kip1 Controls Its Cyclin D-cdk4 Inhibitory Activity
James, M. K., Ray, A., Leznova, D., & Blain, S. W. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.02171-06 · Cited by 134
Bisi, J., Sorrentino, J. A., Roberts, P. J., Tavares, F. X., & Strum, J. C. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0775 · Cited by 134
Yadav, V., Burke, T. F., Huber, L., Van Horn, R. D., Zhang, Y., Buchanan, S. G., Chan, E. M., Starling, J. J., Beckmann, R. P., & Peng, S.-B. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0257 · Cited by 132
MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in Cancer
de Leeuw, R., McNair, C. M., Schiewer, M. J., Neupane, N. P., Brand, L. J., Augello, M. A., Li, Z., Cheng, L. C., Yoshida, A., Courtney, S. M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0410 · Cited by 131
MDM2 antagonists overcome intrinsic resistance to CDK4/6 inhibition by inducing p21
Vilgelm, A. E., Saleh, N., Shattuck-Brandt, R. L., Riemenschneider, K., Slesur, L., Chen, S., Johnson, C. A., Yang, J., Blevins, A., Yan, C. W., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav7171 · Cited by 125
Tan, A. R., Wright, G. S., Thummala, A. R., Danso, M. A., POPOVIC, L. S., Pluard, T., Han, H. S., Vojnović, Ž., Vasev, N., Ma, L., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30616-3 · Cited by 121
Transient Hysteresis in CDK4/6 Activity Underlies Passage of the Restriction Point in G1
Chung, M., Liu, C., Yang, H. W., Köberlin, M. S., Cappell, S. D., & Meyer, T. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.08.020 · Cited by 116
Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia
Pikman, Y., Alexe, G., Roti, G., Conway, A. S., Furman, A. A., Lee, E. S., Place, A. E., Kim, S., Saran, C., Modiste, R., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2869 · Cited by 115
CDK4/6 regulate lysosome biogenesis through TFEB/TFE3
Yin, Q., Jian, Y., Xu, M., Huang, X., Wang, N., Liu, Z., Li, Q., Li, J., Zhou, H., Xu, L., et al. (2020) · The Journal of Cell Biology · doi:10.1083/jcb.201911036 · Cited by 112
p27 Kip1 Inhibits Cyclin D-Cyclin-Dependent Kinase 4 by Two Independent Modes
Ray, A., James, M. K., Larochelle, S., Fisher, R. P., & Blain, S. W. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00898-08 · Cited by 110
Cyclin-Dependent Kinase 4 Expression Is Essential for Neu-Induced Breast Tumorigenesis
Reddy, H. K. D. L., Mettus, R. V., Rane, S. G., Graña, X., Litvin, J., & Reddy, E. P. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2639 · Cited by 108
CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma
Olanich, M. E., Sun, W., Hewitt, S. M., Abdullaev, Z., Pack, S., & Barr, F. G. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2955 · Cited by 102
Dual ALK and CDK4/6 Inhibition Demonstrates Synergy against Neuroblastoma
Wood, A., Krytska, K., Ryles, H. T., Infarinato, N. R., Sano, R., Hansel, T. D., Hart, L. S., King, F. J., Smith, T. R., Ainscow, E., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1114 · Cited by 101
MYC status as a determinant of synergistic response to Olaparib and Palbociclib in ovarian cancer
Yi, J., Liu, C., Tao, Z., Wang, M., Jia, Y., Sang, X., Shen, L., Xue, Y., Jiang, K., Luo, F., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.03.027 · Cited by 101
Yu, J., Yan, J., Guo, Q., Chi, Z., Tang, B., Zheng, B., Yu, J., Yin, T., Cheng, Z., Wu, X., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0475 · Cited by 100
Fassl, A., Brain, C. T., Abu-Remaileh, M., Stukan, I., Butter, D., Stępień, P., Feit, A. S., Bergholz, J. S., Michowski, W., Otto, T., et al. (2020) · Science Advances · doi:10.1126/sciadv.abb2210 · Cited by 98
Self-citationSaab, R. H., Bills, J. L., Miceli, A. P., Anderson, C., Khoury, J. D., Fry, D. W., Navid, F., Houghton, P. J., & Skapek, S. X. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0383 · Cited by 96
Romano, G., Chen, P.-L., Song, P., McQuade, J. L., Liang, R. J., Liu, M., Roh, W., Duose, D. Y., Carapeto, F. C. L., Li, J., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0745 · Cited by 96
Kim, S., Tiedt, R., Loo, A. T., Horn, T. L., Delach, S. M., Kovats, S., Haas, K., Engstler, B. S., Cao, Z. A., Pinzon-Ortiz, M. C., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.26215 · Cited by 96
FOXM1 regulates proliferation, senescence and oxidative stress in keratinocytes and cancer cells
Smirnov, A., Panatta, E., Lena, A. M., Castiglia, D., Daniele, N. D., Melino, G., & Candi, E. (2016) · Aging · doi:10.18632/aging.100988 · Cited by 91
Pek, M., Yatim, S. M. J. M., Chen, Y., Li, J., Gong, M., Jiang, X., Zhang, F., Zheng, J., Wu, X., & Yu, Q. (2017) · Oncogene · doi:10.1038/onc.2017.120 · Cited by 86
Long, F., He, Y., Fu, H., Li, Y., Bao, X., Wang, Q., Wang, Y., Xie, C., & Lou, L. (2019) · Cancer Science · doi:10.1111/cas.13957 · Cited by 86
Rb and FZR1/Cdh1 determine CDK4/6-cyclin D requirement in C. elegans and human cancer cells
The, I., Ruijtenberg, S., Bouchet, B. P., Cristobal, A., Prinsen, M. B. W., van Mourik, T., Koreth, J., Xu, H., Heck, A. J. R., Akhmanova, A. S., et al. (2015) · Nature Communications · doi:10.1038/ncomms6906 · Cited by 82
CDK6 protects epithelial ovarian cancer from platinum‐induced death via FOXO3 regulation
Dall’Acqua, A., Sonego, M., Pellizzari, I., Pellarin, I., Canzonieri, V., D’Andrea, S., Benevol, S., Sorio, R., Giorda, G., Califano, D., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201607012 · Cited by 80
CDK4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclib
Raspé, E., Coulonval, K., Pita, J. M. G., Paternot, S., Rothé, F., Twyffels, L., Brohée, S., Craciun, L., Larsimont, D., Kruys, V., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201607084 · Cited by 77
CDK6 Antagonizes p53-Induced Responses during Tumorigenesis
Bellutti, F., Tigan, A.-S., Nebenfuehr, S., Dolezal, M., Zojer, M., Grausenburger, R., Hartenberger, S., Kollmann, S., Doma, E., Prchal‐Murphy, M., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0912 · Cited by 77
Teh, J. L. F., Cheng, P. F., Purwin, T. J., Nikbakht, N., Patel, P. S., Chervoneva, I., Ertel, A., Fortina, P. M., Kleiber, I., HooKim, K., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0699 · Cited by 74
Genetic Reevaluation of the Role of F-Box Proteins in Cyclin D1 Degradation
Kanie, T., Onoyama, I., Matsumoto, A., Yamada, M., Nakatsumi, H., Tateishi, Y., Yamamura, S., Tsunematsu, R., Matsumoto, M., & Nakayama, K. I. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.06570-11 · Cited by 73
Martin, C. A., Cullinane, C. M., Kirby, L., AbuHammad, S., Lelliott, E. J., Waldeck, K., Young, R. J., Brajanovski, N., Cameron, D. P., Walker, R., et al. (2017) · International Journal of Cancer · doi:10.1002/ijc.31220 · Cited by 70
Knudsen, E. S., Kumarasamy, V. M., Ruiz, A., Sivinski, J., Chung, S., Grant, A. D., Vail, P. J., Chauhan, S. S., Jie, T., Riall, T. S., et al. (2019) · Oncogene · doi:10.1038/s41388-018-0650-0 · Cited by 67
Differential Regulation of G1 CDK Complexes by the Hsp90-Cdc37 Chaperone System
Hallett, S. T., Pastok, M. W., Morgan, R. M. L., Wittner, A., Blundell, K. L. I. M., Felletár, I., Wedge, S. R., Prodromou, C., Noble, M. E. M., Pearl, L. H., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.10.042 · Cited by 66
Rubio, C., Martínez‐Fernández, M., Segovia, C., Lodewijk, I., Suárez-Cabrera, C., Segrelles, C., López-Calderón, F., Munera-Maravilla, E., Santos, M., Bernardini, A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0685 · Cited by 64
Bowe, D. B., Kenney, N. J., Adereth, Y., & Maroulakou, I. G. (2002) · Oncogene · doi:10.1038/sj.onc.1205025 · Cited by 61
Yin, L., Li, H., Liu, W., Yao, Z., Cheng, Z., Zhang, H., & Zou, H. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.12.003 · Cited by 54
Haines, E., Chen, T., Kommajosyula, N., Chen, Z., Herter-Sprie, G. S., Cornell, L., Wong, K., & Shapiro, G. I. (2018) · Oncotarget · doi:10.18632/oncotarget.25803 · Cited by 54
Patel, P. M., Asbach, B., Shteyn, E., Gomez, C., Coltoff, A. R., Bhuyan, S., Tyner, A. L., Wagner, R., & Blain, S. W. (2015) · Molecular and Cellular Biology · doi:10.1128/mcb.01206-14 · Cited by 53
Kinase-independent function of E-type cyclins in liver cancer
Geng, Y., Michowski, W., Chick, J. M., Wang, Y. E., Jecrois, M., Sweeney, K. E., Liu, L., Han, R. C., Ke, N., Zagożdżon, A., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1711477115 · Cited by 52
Self-citationTempka, D., Tokarz, P., Chmielewska, K., Kluska, M., Pietrzak, J., Rygielska, Z., Virág, L., & Robaszkiewicz, A. (2017) · Redox Biology · doi:10.1016/j.redox.2017.12.017 · Cited by 50
PDLIM7 and CDH18 regulate the turnover of MDM2 during CDK4/6 inhibitor therapy-induced senescence
Klein, M. E., Dickson, M. A., Antonescu, C. R., Qin, L., Dooley, S. J., Barlas, A., Manova, K., Schwartz, G. K., Crago, A. M., Singer, S., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0332-y · Cited by 50
SLC36A1-mTORC1 signaling drives acquired resistance to CDK4/6 inhibitors
Yoshida, A., Bu, Y., Qie, S., Wrangle, J. M., Camp, E. R., Hazard, E. S., Hardiman, G., de Leeuw, R., Knudsen, K. E., & Diehl, J. A. (2019) · Science Advances · doi:10.1126/sciadv.aax6352 · Cited by 47
The CDK4/CDK6 inhibitor PD0332991 paradoxically stabilizes activated cyclin D3-CDK4/6 complexes
Paternot, S., Bianca, C., Bisteau, X., & Roger, P. P. (2014) · Cell Cycle · doi:10.4161/15384101.2014.946841 · Cited by 43
CDK4 Regulates Lysosomal Function and mTORC1 Activation to Promote Cancer Cell Survival
Martínez-Carreres, L., Puyal, J., Leal-Esteban, L. C., Orpinell, M., Castillo-Armengol, J., Giralt, A., Dergai, O., Moret, C., Barquissau, V., Nasrallah, A., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0708 · Cited by 43
Gao, Y., Shen, J. K., Choy, E., Mankin, H. J., Hornicek, F. J., & Duan, Z. (2017) · Cellular Oncology · doi:10.1007/s13402-017-0316-x · Cited by 41
Cao, J. Q., Zhu, Z., Wang, H., Nichols, T. C., Lui, G. Y. L., Deng, S., Rejto, P. A., VanArsdale, T. L., Hardwick, J. S., Weinrich, S. L., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0708-7 · Cited by 41
Nur, S. Z., Bernard, K. B. L., Zheng, W. W., Iuan, S. C., Pei, S. Y., Gan, C. P., Kein, S. M., Zainal, A. A. R., Gutkind, J. S., Vyomesh, P., et al. (2019) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2018.0257 · Cited by 40
Mayer, E. L., Gnant, M. I., DeMichele, A. M., Martín, M., Burstein, H. J., Prat, A., Rubovszky, G., Miller, K. D., Pfeiler, G., Winer, E. P., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.08.2240 · Cited by 29
Fbxl8 suppresses lymphoma growth and hematopoietic transformation through degradation of cyclin D3
Yoshida, A., Choi, J., Jin, H. R., Li, Y., Bajpai, S., Qie, S., & Diehl, J. A. (2020) · Oncogene · doi:10.1038/s41388-020-01532-4 · Cited by 26
Obesity/Type 2 Diabetes-Associated Liver Tumors Are Sensitive to Cyclin D1 Deficiency
Luo, C., Liang, J., Sharabi, K., Hatting, M., Perry, E. A., Tavares, C. D. J., Goyal, L., Srivastava, A., Bilodeau, M., Zhu, A. X., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-0106 · Cited by 21
Gottesman, S. R. S., Somma, J., Tsiperson, V., Dresner, L., Govindarajulu, U. S., Patel, P. M., & Blain, S. W. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0188 · Cited by 15
Lin, S., Zhao, X., Li, T., Zhang, H., Tan, H., Wang, X., Jiang, L., Liu, Y., Sun, J., Linghu, L., et al. (2019) · Cancer Research · doi:10.1158/1538-7445.am2019-4425 · Cited by 11
Cited by
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01823-2 · Cited by 720
Cyclin-dependent protein kinases and cell cycle regulation in biology and disease
Pellarin, I., Dall’Acqua, A., Favero, A., Segatto, I., Rossi, V., Crestan, N., Karimbayli, J., Belletti, B., & Baldassarre, G. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02080-z · Cited by 304
Zhai, J., Gu, X., Liu, Y., Hu, Y., Jiang, Y., & Zhang, Z. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1152934 · Cited by 131
Cyclers’ kinases in cell division: from molecules to cancer therapy
Milletti, G., Colicchia, V., & Cecconi, F. (2023) · Cell Death & Differentiation · doi:10.1038/s41418-023-01196-z · Cited by 39
Computational challenges of cell cycle analysis using single cell transcriptomics
Chervov, A., & Zinovyev, A. (2022) · arXiv · doi:10.48550/arxiv.2208.05229 · Cited by 4
Metadata
- Authors
- Fassl, A., Geng, Y., & Sicinski, P.
- Venue
- Science
- Published
- 2022-01-14
- Volume
- 375
- Issue
- 6577
- Pages
- eabc1495-eabc1495
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W4206127585
- Cited by
- 464
- References
- 161
- FWCI
- 54.83
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.